FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

Tesamorelin

Egrifta / TH9507

Growth Hormone Secretagogues

Tesamorelin (trade name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability and receptor binding. It is the only FDA-approved GHRH analog, specifically indicated for the reduction of excess abdominal/visceral fat in HIV-infected patients with lipodystrophy. Its mechanism stimulates pulsatile endogenous GH release from the pituitary gland, preserving normal physiological feedback regulation unlike exogenous GH administration.

作用机制

Synthetic GHRH analog with a trans-3-hexenoic acid modification for enhanced stability. Specifically targets visceral adipose tissue reduction via GH-mediated lipolysis. FDA-approved mechanism preserves physiologic GH pulsatility and IGF-1 negative feedback.

研究协议

仅供研究使用,非医疗建议。

FDA-approved protocol: 2mg daily via subcutaneous injection. Research protocols follow the same dosing. Administered at a consistent time daily, typically in the morning.

研究笔记

Clinical Research Status

Tesamorelin received FDA approval in November 2010 for the treatment of HIV-associated lipodystrophy and is marketed by Theratechnologies as Egrifta and Egrifta SV (single-vial formulation). Multiple Phase III clinical trials (including the landmark studies with over 800 HIV patients) demonstrated statistically significant visceral adipose tissue reduction of approximately 15-18% over 26 weeks. Ongoing research explores applications in non-alcoholic fatty liver disease (NAFLD), cognitive decline in aging and HIV, and broader metabolic syndrome indications beyond the HIV population.

Key Published Findings

Pivotal trials demonstrated that tesamorelin 2mg daily subcutaneous injection reduced visceral adipose tissue by a mean of 15.2% versus placebo over 26 weeks, with continued maintenance of reduction over 52 weeks of treatment. A landmark study published in Neurology showed tesamorelin improved cognitive function in older adults with mild cognitive impairment or subjective cognitive complaints, suggesting neuroprotective properties mediated through GH/IGF-1 signaling. Research has also demonstrated improvements in liver fat content and NAFLD biomarkers, with hepatic fat reduction of approximately 35% in HIV patients with fatty liver.

Safety Profile

Tesamorelin is generally well-tolerated with the most common adverse effects being injection site reactions (erythema, pruritus, pain) reported in approximately 8-13% of clinical trial participants. Fluid retention, arthralgia, and paresthesias occur at rates slightly above placebo, consistent with physiological GH elevation. The compound is contraindicated in pregnancy, patients with active malignancy, and those with disruption of the hypothalamic-pituitary axis, and carries warnings regarding potential glucose intolerance.

Drug Interactions & Contraindications

Tesamorelin may reduce the efficacy of cortisol replacement therapy by increasing cortisol-binding globulin, and patients on glucocorticoid replacement should be monitored. It should be used cautiously with drugs affecting glucose metabolism (insulin, oral hypoglycemics) as GH elevation can impair insulin sensitivity. The compound is contraindicated in patients with active malignancy due to the proliferative effects of elevated GH/IGF-1, and patients with a history of hypothalamic-pituitary tumors should not use it.

Comparison to Related Compounds

Unlike synthetic GH (somatropin) which provides a constant supraphysiological GH level, tesamorelin preserves the natural pulsatile pattern of GH release and maintains hypothalamic-pituitary feedback, resulting in a more physiological GH profile. Compared to CJC-1295 (a modified GHRH analog popular in peptide research), tesamorelin has the advantage of FDA approval, extensive clinical trial data, and insurance coverage for qualifying HIV patients. Sermorelin is a shorter GHRH fragment (1-29) with similar mechanism but lower potency and shorter half-life, requiring more frequent dosing.

Community Observations

Practitioners and patients report that the visceral fat reduction becomes measurable on DEXA scans within 3-4 months, with peak effects at 6-9 months of consistent daily use. The research and TRT community has adopted tesamorelin for its GH-elevating effects beyond the HIV population, noting improvements in sleep quality, body composition, and skin quality. Users frequently note that results reverse within 3-6 months of discontinuation, indicating the need for ongoing treatment, and many physicians prescribe it alongside testosterone replacement therapy for synergistic metabolic benefits.

半衰期

~26-38 minutes

复溶

Sterile water (provided with kit)

存储

冻干

Refrigerate 2-8C. Protect from light.

复溶后

Use immediately after reconstitution. Discard unused portion.

美国法律状态

FDA-approved (Rx only)

又称作

EgriftaTH9507

常见问题

什么是 Tesamorelin?

Tesamorelin (trade name Egrifta) is a synthetic growth hormone-releasing hormone (GHRH) analog consisting of the full 44-amino-acid sequence of human GHRH with a trans-3-hexenoic acid modification at the N-terminus to improve stability and receptor binding. It is the only FDA-approved GHRH analog, specifically indicated for the reduction of excess abdominal/visceral fat in HIV-infected patients with lipodystrophy. Its mechanism stimulates pulsatile endogenous GH release from the pituitary gland, preserving normal physiological feedback regulation unlike exogenous GH administration.

Tesamorelin 如何起作用?

Synthetic GHRH analog with a trans-3-hexenoic acid modification for enhanced stability. Specifically targets visceral adipose tissue reduction via GH-mediated lipolysis. FDA-approved mechanism preserves physiologic GH pulsatility and IGF-1 negative feedback.

Tesamorelin 在美国的监管状态是什么?

FDA-approved (Rx only)

Tesamorelin 的半衰期是多少?

~26-38 minutes

Tesamorelin 还有哪些名称?

Egrifta, TH9507

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明